The University of Chicago Medicine

What The University of Chicago Medicine does

The University of Chicago Medicine is a not-for-profit academic medical center founded in 1927 and operated by the University of Chicago. Its seven-hospital clinical enterprise, led by President Tom Jackiewicz, integrates patient care, biomedical research, and medical education (through the Pritzker School of Medicine and Biological Sciences Division) across a flagship Hyde Park campus, Ingalls Memorial Hospital, Comer Children's Hospital, UChicago Medicine Crown Point in Northwest Indiana, and multiple outpatient sites spanning downtown Chicago, the South Side, and south suburbs. The system is anchored by an NCI-Designated Comprehensive Cancer Center (leading Illinois with 1,000+ clinical trials and 300+ active therapeutic oncology trials annually), the only Adult Level 1 Trauma Center serving Chicago's South Side (reopened May 2018 after 30 years), and over 850 physician faculty members delivering primary, specialty, pediatric, trauma, and transplant care.

The institution's technology footprint combines advanced clinical infrastructure — including an intraoperative MRI suite (one of 12 in the US), FDA 510(k)-cleared Layer 7 brain-computer interface research, and Vanquish water vapor ablation for prostate cancer — with AI capabilities spanning ambient clinical documentation (burnout reduction from 52% to 39%), computer vision diagnostics (EchoGo Amyloidosis), polygenic risk score models for breast cancer in women of African ancestry (trained on 36,000+ women), and remote patient monitoring (34% reduction in infection-related ED visits). Partnerships span pharmaceutical co-development (AbbVie through 2027, Eledon, NewcelX), medical device innovation (Precision Neuroscience, Francis Medical), multi-site clinical research (Mount Sinai, Sheba, Evinature), telehealth (KeyCare Medical Group), and international education (Taiwan Ministry of Health and Welfare).

The business model is multi-stream: (1) patient care services delivered across inpatient, outpatient, virtual, and pediatric settings, billed through insurance with personalized estimates and CMS-mandated price transparency, (2) clinical trial and research revenue from pharma/device sponsors and federal funding (NIH), and (3) community benefit programming — the system invested $1.1B in community benefits for fiscal 2025. As a not-for-profit under academic governance, the institution reinvests margins into research, capital projects (including the 575,000 sq ft AbbVie Foundation Cancer Pavilion opening 2027), and population health initiatives on Chicago's South Side. The enterprise has no external private equity or venture capital investors.

Name

The University of Chicago Medicine

Legal name

The University of Chicago Medical Center

Website

https://uchicagomedicine.org

Company type

Private

Founded year

1927

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The University of Chicago Medicine is a not-for-profit academic medical center operating a seven-hospital enterprise across Chicago and Northwest Indiana, delivering patient care, biomedical research, and medical education through an NCI-Designated Comprehensive Cancer Center, Adult Level 1 Trauma Center, and 850+ physician faculty.

Ownership category

akta.pro rank

Product category

Academic Medical Center Services

NAICS

General Medical and Surgical Hospitals (62211), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (except Mental Health Specialists) (621111), Offices of Physicians (62111)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Schools (MD/DO Granting) (EDAHAGAB), Children’s Hospitals & Pediatric Health Systems (HLAFAJAG), Medical Oncology (HLAKAFAB)

Keywords

• Academic medical center
• Cancer treatment services
• Clinical research trials
• Pediatric hospital care
• Trauma center services

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others, Marketing or Sales

Revenue model

1. Patient Care Services: Healthcare services including inpatient hospital care, outpatient clinics, physician practices, specialty care, emergency services, and surgical procedures. Services provided at flagship Hyde Park campus, multiple outpatient centers, Ingalls Memorial Hospital, and UChicago Medicine Crown Point.
2. Clinical Trials & Research: Conducting clinical trials for pharmaceutical and medical device partners. More than a thousand clinical trials conducted yearly, including over 300 open therapeutic cancer trials enrolling more than 1,000 patients annually.
3. Community Benefit & Public Health Programs: Not-for-profit academic medical center providing community health programs, violence recovery services, and population health initiatives. Invested $1.1 billion in community benefits for fiscal 2025.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

The University of Chicago Medicine is a not-for-profit academic medical health system delivering inpatient hospital care, outpatient specialty and primary care, emergency and Level 1 trauma services, pediatric care through Comer Children's Hospital, comprehensive cancer treatment through its NCI-designated Comprehensive Cancer Center, and organ transplantation across a flagship Hyde Park campus plus Ingalls Memorial Hospital, Crown Point, and seven suburban outpatient sites. The system also operates more than 1,000 active clinical trials per year and integrates medical education through the Pritzker School of Medicine and Biological Sciences Division.

Product overview

The University of Chicago Medicine is a comprehensive academic medical health system offering patient care, research, and medical education through its flagship Hyde Park campus, Comer Children's Hospital, Ingalls Memorial Hospital, and multiple outpatient clinics across Chicago, suburbs, and Northwest Indiana. The system provides a broad portfolio including primary care, specialty care, cancer treatment through its NCI-designated Comprehensive Cancer Center, pediatric care, trauma services, virtual/telehealth services, and more than 1,000 clinical trials annually. Key platforms include the MyChart patient portal for digital access to medical records and scheduling, and the forthcoming AbbVie Foundation Cancer Pavilion (575,000 sq ft, opening 2027). Specialized services include mobile dental units, intraoperative MRI capabilities, and innovative surgical programs. The organization conducts pioneering research spanning cancer, organ transplantation, diabetes, cardiology, neuroscience, and other fields.

Differentiator

Problem solved

Functional benefit

Products and services

• UChicago Medicine Comprehensive Cancer Center NCI-designated Comprehensive Cancer Center providing personalized cancer care across all cancer types through world-renowned physicians backed by pioneering research and clinical trials.
• Comer Children's Hospital

Quantifiable outcome

• Trauma center served 6,000+ patients generating positive operating revenue in 2024
• +5 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability9 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• NewcelX Ltd.minorStrategic or Co-development Partner · 4 June 2026Collaborative research agreement to combine immune modulation with islet replacement therapy for type 1 diabetes.
• Precision Neuroscience CorporationcoreStrategic or Co-development Partner · 30 April 2026Clinical partnership to advance AI-driven sensorimotor function and neuroprosthetics research using Precision's Layer 7 brain-computer interface technology. UChicago Medicine adds to Precision's growing clinical research network, building on decade-long involvement in landmark human BCI trials. Research aims to help patients with ALS or brainstem stroke.
• KeyCare Medical GroupminorChannel Partner/ Reseller/ Distributor · 1 April 2026Contract partner providing Virtual Urgent Care services to UChicago Medicine patients through KeyCare's platform for 24/7 telehealth access.
• Mount SinaiminorStrategic or Co-development Partner · 18 March 2026Co-researchers with University of Chicago Medicine on DoD-funded ulcerative colitis clinical trial investigating CurQD nutraceutical formulation combined with vedolizumab.
• Sheba Medical CenterminorStrategic or Co-development Partner · 18 March 2026Co-researchers with University of Chicago Medicine and Mount Sinai on DoD-funded ulcerative colitis clinical trial. Located in Israel.
• AbbViecoreStrategic or Co-development Partner · 23 December 2025Extended collaboration agreement through 2027 to advance oncology research and clinical trials, building on partnership that began in 2016. Collaboration aims to accelerate translational research, streamline clinical trial operations, and improve patient outcomes in cancer treatment. Enhanced infrastructure including AbbVie Foundation Cancer Pavilion opening in 2027.
• Taiwan Ministry of Health and WelfareminorStrategic or Co-development Partner · 1 November 2025Partnership through memorandum of understanding signed November 2025 to cultivate clinical health IT leaders in Taiwan. Approximately 50 Taiwanese physician executives nominated by medical centers participate in online courses through Taiwan Smart Healthcare School, with select group undergoing six-month on-site training at University of Chicago Medical Center.
• Breakthrough T1DminorOthersFunding partner for islet cell transplantation trial of tegoprubart for type 1 diabetes patients at University of Chicago Medicine Transplant Institute.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Cedars-Sinai Medical Center: Large nonprofit academic medical center with NCI-designated cancer program and extensive research arm. Comparable on scale, clinical-trial breadth, and specialty procedure volume, though serving a different geography.
• Mount Sinai Health System: New York City academic health system integrating Icahn School of Medicine with multiple hospitals including Tisch Cancer Center (NCI-designated). Active research collaborator with UChicago on DoD-funded ulcerative colitis trial. Comparable on scale and tripartite mission.
• UCLA Health: Major public-university AMC with Jonsson Comprehensive Cancer Center (NCI-designated), Level 1 trauma, and large children's hospital. Comparable across mission, scale, and academic complexity.
• Penn Medicine (University of Pennsylvania Health System): Ivy League academic medical system with NCI-designated Abramson Cancer Center, hospital-of-the-University-of-Pennsylvania, and large research portfolio. Comparable on AMC scale, NCI designation, and complex care depth.
• UCSF Health: Academic medical system of UCSF with NCI-designated Helen Diller Family Comprehensive Cancer Center, major research footprint, and pediatric services via UCSF Benioff Children's Hospital. Comparable on research intensity and academic scope.

Direct peers

• University of Michigan Health (Michigan Medicine): Public research university AMC with NCI-designated Rogel Cancer Center, Level 1 trauma, and major children's hospital. Comparable as a top-tier academic enterprise with tripartite care/research/education mission.
• Johns Hopkins Medicine: Elite private academic medical system integrating Johns Hopkins Hospital, Sidney Kimmel Cancer Center (NCI-designated), and a major research medical school. Direct comparable on tripartite mission scale, NCI designation, and clinical trial leadership.
• Northwestern Medicine: Flagship academic medical system in Chicago with Northwestern Memorial Hospital, Feinberg School of medicine, and NCI-designated Robert H. Lurie Comprehensive Cancer Center. Direct competitor for tertiary referrals, oncology volumes, and research funding in the same metro.
• Rush University Medical Center: Chicago academic medical center with Rush Medical College and strong tertiary programs. Competes directly with UChicago Medicine for complex care referrals, physician talent, and clinical trial volume in the same metropolitan market.
• Northwestern Medicine - Lurie Children's Hospital: Premier Chicago children's hospital and competing pediatric tertiary/quaternary referral destination. Most direct peer to Comer Children's Hospital for complex pediatric cases, pediatric oncology, and pediatric research.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/uchicagomed
• Facebookfacebook.com/UChicagoMed
• LinkedInlinkedin.com/company/university-of-chicago-medicine

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The University of Chicago Medicine